Stress myocardial perfusion single photon emission computed tomography (MPS) plays an important role in risk assessment of patients with known or suspected coronary artery disease (CAD). It has been shown to risk stratify a variety of patient populations and, when incorporated in an overall testing strategy, lower the overall cost and enhance the effectiveness of testing (1) (2) (3) . The low risk associated with normal MPS is an important component of these findings-by identifying patients at sufficiently low risk for subsequent events, they can be safely managed medically, and additional, costly testing and interventions can be avoided (1) (2) (3) (4) .
To date, most studies examining risk after a normal MPS have reported rates of hard events (HE) (cardiac death or nonfatal myocardial infarction [MI] ) of Ͻ1% per year of follow-up. Many have claimed that this low risk is independent of imaging type (single photon emission computed tomography [SPECT] vs. planar), stress performed (exercise vs. pharmacologic), isotope used, clinical characteristics, or previous history of CAD (1) (2) (3) (5) (6) (7) (8) (9) (10) (11) (12) (13) . However, studies of patients undergoing pharmacologic stress, a population at higher risk, and more comorbidities than patients undergoing exercise have reported HE rates of 1.3% to 2.7% per year (14 -18) , suggesting that underlying clinical risk and previous CAD may influence event rates after a normal MPS. Thus, although MPS provides incremental prognostic information over clinical information alone, it appears that clinical information also yields incremental prognostic value over MPS data after normal MPS. Further, if these clinical and historical factors also affect the temporal characteristics of this risk, how long risk remains low after a normal MPS may be dictated by clinical and historical characteristics.
To date, MPS prognosis studies have expressed results as cumulative event rates, and normal MPS are considered to indicate low risk if the event rate is below 1% per year. Knowledge of this event rate alone, however, is potentially misleading. For example, while an event rate of Ͼ1% per year after a normal MPS may be the result of a constant Ͼ1% per year event rate over the follow-up interval, it may also result from an event rate of Ͻ1% during the first year and a markedly increased event rate later in the follow-up period. Similarly, even an event rate of Ͻ1% per year over more than one year does not exclude the possibility that risk was exceedingly low initially, but increased with time, and risk was not Ͻ1% later. These temporal characteristics of risk (how risk changes with time) are as yet undefined but may be important in determining MPS test performance.
The goals of the current study were to: 1) determine whether clinical factors alter risk for HE after normal MPS; 2) identify the predictors of increased risk and shortened survival time in patients with normal MPS; and 3) determine the impact of these predictors on the length of time that patients remain at low risk after the index normal MPS, hence defining whether a "warranty" period exists.
METHODS
Study population. We identified 16,187 consecutive patients who underwent dual-isotope MPS between January 1, 1991 and March 27, 1997 (Fig. 1) . Patients with valvular heart disease or primary cardiomyopathy were excluded from this study. Of the initial population, 712 patients (4.4%) were lost to follow-up. Of the remaining patients, 8,019 were excluded because of abnormal scans, leaving a study population of 7,456 patients with normal MPS. Of these, 80 patients who underwent SPECT within 90 days after percutaneous transluminal coronary angioplasty (PTCA) were excluded owing to the relative instability of their disease, thus leaving 7,376 patients in this study (48% of the follow-up population). Patients with previous MI or revascularization were considered to have known CAD. Rest thallium (Tl)-201 imaging. All patients underwent stress dual-isotope SPECT as previously described (19, 20) . Whenever possible, beta-blockers and calcium channel antagonists were terminated 48 h before testing. Initially, Tl-201 (2.5 to 3.5 mCi) was injected intravenously at rest, with dose variation based on patient weight, and rest Tl-201 imaging was initiated 10 min afterward. Exercise stress protocol. All patients performed a symptom-limited treadmill exercise test using standard protocols. At near maximal exercise, a 20-to 30-mCi dose of technetium (Tc)-99m sestamibi was injected (actual patient dose varied with patient weight) and exercise continued for 1 min after injection. The Tc-99m sestamibi SPECT imaging was begun 15 to 30 min after isotope injection (19) . Adenosine stress protocol. Patients were instructed not to consume coffee or other products containing caffeine for 24 h before MPS. After rest Tl-201 SPECT, infusion (140 g/kg/min for 6 min) was performed, and Tc-99m sestamibi was injected at the end of the third minute of infusion. Single photon emission computed tomography was initiated approximately 60 min after adenosine infusion (19) .
During both types of stress, 12-lead electrocardiographic recording was performed each minute of stress with continuous monitoring of leads aVF, V 1 , and V 5 . Blood pressure was measured and recorded at rest, at the end of each exercise stage, and at peak exercise. Maximal degree of ST-segment change at 80 ms after the J point of the electrocardiogram (ECG) was measured and assessed as horizontal, upsloping, or downsloping. SPECT acquisition protocol. Myocardial perfusion single photon emission computed tomography was performed as previously described (19, 20) using a circular or elliptical 180°acquisition for 64 projections at 20 s per projection. Images were subject to quality control measures as previously described (20) . No attenuation or scatter correction was used. After filtered back-projection, short-axis, vertical, and horizontal long-axis tomograms were generated. Image interpretation. Semiquantitative visual interpretation used short-axis and vertical long-axis tomograms di-
Abbreviations and Acronyms
CAD ϭ coronary artery disease ECG ϭ electrocardiogram ETT ϭ exercise tolerance test HE ϭ hard event MI ϭ myocardial infarction MPHR ϭ maximal predicted heart rate MPS ϭ myocardial perfusion single photon emission computed tomography PTCA ϭ percutaneous transluminal coronary angioplasty SPECT ϭ single photon emission computed tomography Tc ϭ technetium Tl ϭ thallium Figure 1 . Outline of patient selection. PTCA ϭ percutaneous transluminal coronary angioplasty; SPECT ϭ single photon emission computed tomography.
vided into 20 segments (2,4). Each segment was scored by consensus of two experienced observers using a five-point scoring system (0 ϭ normal, 1 ϭ equivocal, 2 ϭ moderate, 3 ϭ severe reduction of uptake, and 4 ϭ absence of detectable tracer uptake). A summed stress score (SSS) was obtained by adding the scores of the 20 segments of the stress sestamibi images; SSS Ͻ4 was considered normal (2, 4 were described as a frequency, and continuous variables were described as a mean Ϯ SD (25th and 75th percentiles). Observed, attributable, and relative risks were calculated. Attributable risk is defined as the risk in exposed individuals that can be attributed to the exposure. This measure is derived by subtracting the event rate in nonexposed persons from the corresponding rate among exposed individuals. Relative risk is defined as the ratio of the risk among those exposed to the risk among those not exposed. A p value of Ͻ0.05 was considered significant. Cox proportional hazards analysis was used to determine the predictors of adverse outcomes, and parametric survival models (accelerated failure time models) were used to identify which variables influenced time to event and to estimate risk-adjusted event rates at specific time intervals and the length of time to specific risk thresholds. First, models were developed to identify variables most predictive of events, using a stepwise approach employing the most significant univariable predictors from Tables 1 and 2 . Variables were first categorized into the following groups: 1) cardiac risk factors (age, hypertension, diabetes, pre-scan likelihood); 2) abnormal rest ECG, stress type, medications, symptoms; and 3) in patients with known CAD, historical variables. The most predictive variables from each of these were entered into a final model. For parametric survival analyses, separate models were developed for patients with versus without previous CAD. Based on the distribution of survival times in our cohort, a Weibull distribution was selected for the parametric models (22, 23) . All multivariable modeling was performed using S plus 2000 (Insightful Categorical variables are described as % (n), continuous variables as mean Ϯ SD (25th, 75th percentiles). Risk is expressed as event rate over follow-up period. Continuous variables are dichotomized at the level of the 75th percentile, except for determination of hazard ratio based on the Cox proportional hazards model. CAD ϭ coronary artery disease; CCB ϭ calcium channel blocker; CD ϭ cardiac death; CoxPH ϭ Cox proportional hazards model (univariable); DM ϭ diabetes mellitus; ECG ϭ electrocardiogram; HE ϭ hard event; HR ϭ hazard ratio; NACP ϭ nonanginal chest discomfort; NTG ϭ nitroglycerin.
Corp., Seattle, Washington). When appropriate, assumptions of linearity, proportional hazards, and multiplicity were tested (22) (23) (24) . Patients undergoing revascularization early after nuclear testing were not censored, because the revascularization was not related to the result of MPS. Although the parametric modeling was used to estimate predicted time to risk and levels of risk at specific time intervals, the limited number of events in this study compromises the accuracy of these estimates, and their purpose is to illustrate the impact of confounders on time and risk. The threshold for entry of variables into models was p Ͻ 0.10.
RESULTS
Outcome events. A total of 78 HE (45 cardiac deaths and 33 non-fatal MI) occurred, representing a 1.1% cumulative HE rate (0.6%/year). The 8,019 patients with abnormal MPS who underwent testing during this time interval experienced 530 HE (6.6% cumulative HE rate), and the 80 patients with normal studies immediately after PTCA (excluded from this study) experienced 5 HE (6.3% cumulative HE rate). Thus, the 15,475 patients tested during this time interval experienced a cumulative HE rate of 4.0% (613 total HE).
For purposes of analysis, patients with normal MPS were separated into those without (6,046 patients; 41 HE, 0.7% cumulative rate) and with known CAD (1,330 patients; 37 HE, 1.3% cumulative rate). Clinical characteristics. The clinical characteristics of these two groups are shown in Tables 1 and 2 . Patients without previous CAD were evenly split by gender (Table  1) , predominantly underwent exercise, and infrequently had diabetes or a history of smoking. Intermediate numbers had hypertension, a family history of CAD, or elevated cholesterol. About a third were asymptomatic, smaller numbers had nonanginal chest discomfort or atypical angina, and fewer had typical angina or dyspnea. The pre-scan likelihood of CAD was low-intermediate. Half had abnormal rest ECG, and few were using anti-ischemic medications.
Patients with known CAD (Table 2) were more often male. One-third of patients had nonanginal chest discomfort, 28% were asymptomatic, and smaller proportions had atypical angina, typical angina, or dyspnea. The pre-scan likelihood of ischemia was low-intermediate. Few patients were taking anti-ischemic medications. Univariate predictors of outcomes. The observed, attributable, and relative risks associated with these clinical characteristics are shown in Tables 1 and 2 . In patients without known CAD (Table 1) , increased age, diabetes, and dyspnea were associated with a greater observed risk of cardiac death or HE. The use of calcium channel blockers was also associated with higher observed risk of HE. Attributable risk was greatest for increasing age, exercise (a protective effect), diabetes, and dyspnea with respect to both HE and cardiac death. Higher relative risks for HE were noted for age, diabetes, and symptoms of dyspnea, with relatively high values present for pre-scan likelihood of CAD, calcium channel blockers, and abnormal rest ECG. Strikingly low relative risks were associated with exercise stress and smoking, and to a lesser extent, with family history of CAD. The relative risk for cardiac death was low for exercise and high for diabetes, dyspnea, and age.
In patients with known CAD (Table 2) , the clinical characteristics associated with greater observed risk of HE or cardiac death included age, hypertension, diabetes, and dyspnea. The use of beta-blockers and nitrates was also associated with higher observed risk of HE. Attributable risk was greatest for age, dyspnea, and nitrate use with respect to cardiac death and age, abnormal rest ECG, and previous angiography for HE. Increased relative risk of HE was noted for age, dyspnea, nitrate use, abnormal rest ECG, and previous angiography. Low relative risks were associated with exercise, smoking, hypercholesterolemia, presentation without symptoms, typical angina, and calcium channel blockers.
Risk and percent maximal heart rate achieved. Of the 5,533 patients who underwent exercise stress, 4,937 (89%) attained target heart rate (Ն85% of maximal predicted heart rate [MPHR]). In addition, 7% achieved 80% to 85%, 3% attained 70% to 80%, and 2.9% achieved Ͻ70% of MPHR. The HE rates in these four subgroups of patients were 0.7%, 0.5%, 1.1%, and 2.9%, respectively. This suggests that prognostically, achieving Ն80% of MPHR is sufficient, but lower MPHR are associated with worse prognosis. Clinical characteristics and predictors of outcomes as a function of presenting symptoms. As a function of presenting symptoms (Table 3 ), significant differences in HE rates were found in all variables examined except for smoking and likelihood of CAD. Significant differences were present as a function of age, gender, type of stress, hypertension, diabetes, family history, cholesterol levels, anti-ischemic medication use, and rest ECG. HE rates in patient subgroups. A significant difference was present with respect to HE rates between patients with versus without a history of CAD (p Ͻ 0.001; 1.4% vs. 0.4% per year, respectively) (Fig. 2) . No such differences were present as a function of type of stress or patient gender. Comparing rates of HE in men and women with versus without diabetes (Fig. 3) , diabetic women had a HE rate of 1.8%/year, with lower rates in the other subgroups. No difference was present in HE rates between men and women either with or without diabetes. However, a difference was present between women with versus without diabetes (pϭ 0.007), although no such difference was present in men. No difference in HE rates was present between patients with versus without known CAD with adenosine stress (Fig. 4) , but a significant difference was present with exercise stress (p Ͻ 0.001).
Multivariable survival analysis.
Cox proportional hazards analysis identified stress type, CAD history, diabetes, gender, and age as the model most predictive of HE. Interactions were present between type of stress and history of CAD as well as between the presence of diabetes and gender (Table 4 ). The final model for prediction of time to HE in patients with no previous CAD included age and gender, the presence of diabetes, and the type of stress. This model included a nonlinear term for age and an interaction between gender and diabetes. In patients with previous CAD, the final model of time to HE included age, gender, diabetes, and previous catheterization. Significant interactions were present between age and gender and between diabetes and gender.
As the model for patients with known CAD did not include stress type but the model for patients without CAD did, the results of subsequent analyses shown in Tables 5  through 8 will show separate results for exercise and adenosine stress patients without CAD but a single set of results in patients with known CAD. Changes in risk with time: event rates as a function of increments of follow-up time. To better understand the temporal change in risk as a function of patient characteristics, we estimated the predicted HE rate at six-month intervals for the first two years after the index study (first, second, third, and fourth 6-month intervals), and summed these to show predicted event rates in the first versus second years of follow-up as well as the overall two-year predicted event rates (Table 5 ).
In patients with no previous CAD undergoing exercise, non-diabetic women had very low predicted event rates at all ages for all six-month intervals examined. These rates were similarly very low in both diabetic and non-diabetic men until age 80, at which point event rates were still relatively low, despite being 2 to 3 times greater than event rates at younger ages. Diabetic women had predicted HE rates that were 4-to 5-fold greater, and, by age 80, reached rates of 1% or more in two of four six-month intervals examined. Patients undergoing adenosine stress had a similar pattern of predicted HE rates (no significant temporal change with a significant age-related trend), but with significantly greater absolute rates of HE.
In comparison to patients without previous CAD, patients with known CAD at the time of SPECT (Table 6) had a similar pattern of increasing risk with age, but greater predicted event rates in all time intervals except in the setting of elderly female diabetics. Patients with known CAD also differed from patients without previous CAD in that female diabetics had event rates similar to male diabetics and non-diabetics; however, non-diabetic women had lower event rates.
The most striking finding in patients with known CAD was that patient risk increased in all patient subgroups in each successive time interval. Comparing the first to the fourth six-month interval, patient risk increased approximately 2 to 2.5 times, and event rates in the first year were lower than in the second year. Hence, risk appears to accelerate over time in patients with known CAD (Fig. 5) .
To further understand the temporal characteristics of risk as a function of patient characteristics, we estimated the predicted time to 0.5%, 1.0%, 1.5%, and 2.0% risk based on the multivariable models, as well as the time from the index study to 0.5% risk, 0.5% to 1.0% risk, 1.0% to 1.5% risk, and 1.5% to 2.0% risk (Tables 7 and 8 ). The latter was performed to determine whether the risk of HE changed over time.
In patients without previous CAD (Table 7 ), predicted time to any level of risk was extremely long in men both with and without diabetes, as well as in non-diabetic women, until advanced age. In these three patient subgroups, time to risk was relatively long (time to 1% risk occurring well beyond 1 year) even at age 80. In diabetic women, however, time to risk was significantly shortened at each age level and reached short intervals (1% risk at Ͻ1 year) by age 80. Examining time to each level of risk reveals that in all four patient subgroups, time to risk shortened only minimally with increasing risk level, implying that risk did not change over time.
In patients with known CAD (Table 8) , time to any level of risk was long in non-diabetic women but was relatively shorter in the three other subgroups at most ages examined (rate of risk Ͼ1% per year). Examining the time intervals between levels of risk, each 0.5% level of predicted risk occurred at shortening intervals, indicating an increase in risk with time after a normal MPS in patients with known CAD (p Ͻ 0.001).
DISCUSSION
We followed a cohort of patients after normal MPS to determine 1) whether clinical factors altered the risk for HE, 2) which factors were predictive of risk, and 3) whether a significant change in risk over time occurred after a normal MPS. Univariable analysis revealed that HE rates were greater in diabetic versus non-diabetic women. Compared with patients without previous CAD undergoing exercise stress, patients with known CAD undergoing exercise stress or patients undergoing adenosine stress were found to have significantly higher event rates. With respect to patients undergoing exercise stress, the risk associated with normal MPS was similar in patients who achieved Ն85% and 80% to 85% of MPHR, but HE rates were higher in patients who achieved Ͻ80% of MPHR. Multivariable survival models revealed that clinical factors dramatically altered both the risk of HE and its temporal characteristics, suggesting that clinical information yields incremental prognostic value over MPS data in patients with normal scans. Cox proportional hazards analysis identified adenosine stress, CAD history, diabetes, gender, and increasing age as the model most predictive of HE, with significant interactions between type of stress and CAD history (lower risk in patients without previous CAD undergoing exercise stress in comparison to all other patients) as well as between the presence of diabetes and patient gender (higher risk in female diabetic patients compared with all other patients). Parametric survival analysis in patients without previous CAD revealed that increasing age, gender, the presence of diabetes, and adenosine stress best predicted HE (with significant interactions between the presence of diabetes and patient gender [higher In patients with previous CAD, the final model of time to HE included increased age and gender, diabetes, and previous catheterization. Based on the parametric survival models, in patients without previous CAD, predicted risk increased (and time to any level of risk decreased) significantly with age, with diabetes in women, and with adenosine stress. For any combination of clinical factors, the level of risk in these patients appeared to stay uniform with time (e.g., the risk in the first 12 months post-MPS was the same as the second 12 months post-MPS). In patients with known CAD, predicted risk also increased (and time to any level of risk decreased) with age and in female diabetics. Importantly, for any combination of clinical factors in patients with CAD, risk increased with time. That is, the risk in the first year was less than in the second year, hence, a dynamic temporal component of risk was present. Of note, absolute predicted risk was greater in patients with known CAD than in patients without previous CAD. Incremental prognostic value of clinical data. We previously suggested (4) that clinical characteristics influence patient outcome after a normal scan based on the finding of a trend of increasing HE rates in patients with normal scans with post-ETT likelihood, Duke treadmill score, or increasing age. Numerous studies have described the incremental prognostic value of MPS data over clinical, historical, and treadmill data for prediction of adverse events. The current study reinforces the importance of the converse of this finding-clinical and historical clinical information yields incremental information over MPS data alone. This indicates that for a normal MPS result, actual patient risk will vary with clinical and historical data. This is consistent with clinical intuition; with normal MPS, an elderly patient with known CAD and revascularization who is unable to perform exercise stress would have a greater risk than a young patient with good exercise tolerance without previous CAD. This information has long been incorporated in clinical practice, as shown by the value of clinical data for predicting referral to catheterization after MPS. Previous studies: prediction of low risk versus defining time intervals with low risk. Although a low risk is associated with normal MPS (1-3,5-13), several recent studies have reported somewhat higher event rates (14 -18) . These rates are generally reported as both cumulative and annualized event rates. As previously stated, an event rate of 3% over a three-year period may be due to: 1) a low constant event rate, 2) an event rate of Ͻ1% in the first year and increasing event rates in subsequent years, or 3) a much higher event rate initially and a lower rate subsequently. To date, post-MPS risk has not been reported as rates within circumscribed time intervals after the index study, an approach that would yield insight into both the change in risk over time and the duration of time after the study that risk remains low. Although previous studies have reported longer follow-ups (12, 17) , no previous reports have assessed the change in risk over time. Clinical implications. The relative differences between therapeutic modalities with respect to mortality or cost vary as a function of the post-intervention timepoint at which they are examined. Although previous studies have shown reductions in short-and long-term costs of care with the addition of nuclear testing to a clinical strategy (1-3), these studies assumed that patients would undergo no further testing after a normal MPS. If repeat testing is needed or resource utilization increases at a certain time interval after a normal scan, the clinical-and cost-effectiveness of strategies incorporating nuclear testing would be significantly altered. However, to fully understand the cost implications for testing strategies, inquiry into temporal variations in risk with alternative testing strategies is necessary.
The finding that patients with a low likelihood of disease referred to MPS are at low risk for a considerable time interval after a normal study implies that these patients probably do not require repeat testing for a number of years. That patient characteristics alter the rate at which risk develops after normal scans suggests that under certain circumstances a reported annualized event rate may misestimate the actual risk. If risk is non-constant over the follow-up period, the annualized event rate will differ from the event rate in each year of the study. A non-constant event rate was present in the current study in patients with known CAD. Study limitations. The patients in this study are those referred to a university-affiliated referral center, potentially limiting generalizability. The scintigraphic studies were assessed by experienced observers using a standardized, semiquantitative approach to visual interpretation (5, 20) . The visual approach was used because at the time of collection of the SPECT studies, we did not have a quantitative analysis technique operating on all of our camera/computer systems. However, the reliance upon the expertise of the observer limits the extrapolation of our results to those of other centers.
Although parametric survival models can accurately estimate predicted time to risk and levels of risk at specific time intervals, the limited number of events in this study compromises the precision of the estimates of risk and time to risk in the current study. In the current study, these estimates are intended to demonstrate the impact of the variables in the model as confounders of risk and time to risk in patients with normal scans. Conclusions. The risk of HE after a normal MPS, and its change over time, are a function of the clinical and historical factors of the patients tested. Hence, clinical factors add incremental value over MPS data alone and alter the time at which repeat testing might be appropriate, hence establishing the existence of a "warranty" period for normal MPS studies.
